Long-Term Treatment in Diabetics with Acarbose, a Glucosidase Inhibitor : Efficacy, Tolerability and Effect on GI Hormones. Tohoku J. exp. Med., 1983, 141, Suppl., 683-686-12 months therapy with acarbose in 143 type I and type II patients markedly improved the metabolic control, assessed by fasting and postprandial blood glucose determination. During 5 year acarbose treatment GIP levels were decreased and enteroglucagon levels were elevated. After withdrawal of the drug for one week GIP levels increased and enteroglucagon concentrations fell. Thus, GI-hormone changes were reversible after discontinuation of acarbose. Tolerability of acarbose was good and clinical chemistry and haematology parame ters showed no changes after 1-5 years acarbose therapy. Approximately 60% of the patients had intestinal symptoms which subsided again for most patients after 1-4 weeks therapy with acarbose. Body weight remained unchanged. The glucosidase inhibitor acarbose is a new effective and safe therapeutic concept in the treatment of diabetes mellitus.
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acarbose ; GI hormones Acarbose, a glucosidase inhibitor, reduces and delays the postprandial rise in blood glucose by competitive inhibition of enzymes in the upper part of the small bowel1-3). This results in improved metabolic control for both forms of diabetes mellitus4). Excessive postprandial hyperglycaemic peaks are avoided and the daily blood glucose profile is evened out, glucose excretion in the urine is reduced and the mean blood glucose levels lowered. This is all reflected in a reduction in MAGE, M-values and HbA1-values as reported by different authors-7 and confirmed also in a longterm study by Sachse and co-workers): They treated 24 sulphonylurea patients first with placebo and then 12 of them for 6months with 300mg acarbose daily and 12 with placebo, then all 24 with sulphonylurea only. They found significant differences in the above mentioned parameters.
We In a different study January 1981 we examined the behaviour of gastrointesti nal hormones in the same 4 patients.
On the first day of the study the patients received a standard breakfast and 200mg acarbose ; the drug was then withdrawn for one week, at the end of which a standard breakfast was again given without acarbose. Blood samples were taken 15min before and at the start of the meal and at 15,30 and 60min intervals for 4 hr following the meal by using an indwelling venous cannula in the arm. Blood glucose and serum insulin levels were determined.
Plasma levels of GIP, enteroglucagon and pancreatic glucagon, motilin, gastrin, VIP (vasoactive intestinal polypeptide), neurotensin, soma tostatin and pancreatic polypeptide were measured by Dr. Bloom at the Hammersmith Hospital, London.
During acarbose treatment blood glucose, serum insulin and plasma GIP levels were markedly depressed. After withdrawal of the drug these values increased again. Plasma enteroglugacon showed an opposite pattern : It was increased during treatment and fell after the withdrawal of acarbose. These findings are in accordance with those of Jenkins, Folsch, Radziuk and Taylor et al. [9] [10] [11] [12] [13] . GIP is known to be a stimulator of insulin secretion under hyperglycaemic conditions. The lowered GIP levels may possibly be involved in the decrease of the serum insulin concentration.
Enteroglucagon, however, was increased during acarbose treatment.
GIP is secreted in the upper small intestine whereas entero glucagon is secreted in the ileum and colon. It therefore appears that the secretion of these peptides is related to the intestinal availability of unabsorbed carbohydrate. After withdrawal of the drug the changes of the GI-hormones were 
